Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training.
stem cells
technology
tissue engineering
tissue regeneration
Journal
Stem cells translational medicine
ISSN: 2157-6580
Titre abrégé: Stem Cells Transl Med
Pays: England
ID NLM: 101578022
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
14
11
2019
revised:
12
02
2020
accepted:
24
02
2020
pubmed:
30
3
2020
medline:
22
7
2021
entrez:
30
3
2020
Statut:
ppublish
Résumé
The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence-enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine.
Identifiants
pubmed: 32222115
doi: 10.1002/sctm.19-0389
pmc: PMC7308637
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
728-733Informations de copyright
© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Références
Nat Biotechnol. 2016 Mar;34(3):312-9
pubmed: 26878319
Cytotherapy. 2017 Dec;19(12):1383-1391
pubmed: 28935190
Biomaterials. 2016 Dec;110:45-59
pubmed: 27710832
Sci Transl Med. 2018 Oct 3;10(461):
pubmed: 30282697
Biologicals. 2017 Nov;50:20-26
pubmed: 28888427
Otolaryngol Head Neck Surg. 2017 Jun;156(6):999-1010
pubmed: 28421875
Stem Cells Dev. 2014 Dec;23 Suppl 1:29-31
pubmed: 25457958
Stem Cells Transl Med. 2020 Jul;9(7):728-733
pubmed: 32222115
Cell. 2018 Apr 19;173(3):792-803.e19
pubmed: 29656897
Anal Chem. 2016 Oct 4;88(19):9753-9758
pubmed: 27560777
Biomater Sci. 2018 May 1;6(5):915-946
pubmed: 29492503
Stem Cells Transl Med. 2013 Nov;2(11):871-83
pubmed: 24101671
Regen Med. 2015;10(1):49-64
pubmed: 25562352
Front Med (Lausanne). 2018 Jun 21;5:178
pubmed: 29977893
Stem Cells Transl Med. 2018 Aug;7(8):564-568
pubmed: 30009571
F1000Res. 2018 Apr 30;7:
pubmed: 29770207
Stem Cells Transl Med. 2015 Feb;4(2):130-5
pubmed: 25575525
Annu Rev Pharmacol Toxicol. 2015;55:439-464
pubmed: 25292428
Pharm Res. 2018 Jul 11;35(9):176
pubmed: 29998405
Acta Biomater. 2017 Jul 1;56:3-13
pubmed: 28342878